<div>
  <ul>
    <li>
      <p>
        Canadian psychedelic company Numinus Wellness has entered a sales agreement with PharmAla Biotech, a Canadian biotechnology company. PharmAla will supply its GMP-certified LaNeo MDMA (3,4-methylenedioxymethamphetamine) for use in Numinus' upcoming clinical trial.
      </p>
    </li>
    <li>
      <p>
        The clinical trial aims to investigate the feasibility of using a group model in MDMA-assisted psychotherapy, enrolling trainee practitioners as participants. This research seeks to determine the optimal number of therapists needed for safe program delivery and provide eligible trainees with practical experience in MDMA-assisted therapy. The trial application has been submitted to Health Canada for approval.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.globenewswire.com/en/news-release/2024/03/26/2852377/0/en/PharmAla-Biotech-Signs-Sale-Agreement-with-Numinus.html">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.benzinga.com/general/biotech/24/03/37945015/two-top-biotechs-forge-mdma-supply-deals-for-clinical-research">
      Benzinga
    </a>
     
  </p>
</div>


Psychedelic Medicine

PROMINENT_CATEGORY

Numinus partners with PharmAla Biotech for LaNeo MDMA supply in clinical trial

<div>
 
 <p>Numinus Wellness, a Canadian psychedelic company, has secured $6 million via a bought deal offering. Those leading this venture were Eight Capital and Stifel GMP, with significant contributions from Integrated VC and the Multidisciplinary Association for Psychedelic Studies. The offering comprised of 50 million units, each priced at $0.12.</p>
 <p>The newly acquired funds will be utilized as working capital and for broader corporate objectives.</p>
 
</div>

Numinus Wellness raises USD 6 million in bought deal funding for operational expenses

Numinus Wellness, a Canadian psychedelic company, has introduced a program to help individuals with mental distress related to serious and chronic illnesses. The program includes psilocybin and ketamine-assisted therapy interventions for cancer patients, as well as projects for end-of-life distress. Numinus aims to expand knowledge and possibilities for psychedelic-assisted therapies, while making them more affordable and accessible for patients.

Numinus launches psychedelic program for mental distress associated with chronic and serious illness

Numinus Wellness provides financial and business update for Q3 FY2023

Numinus partners with HealingMaps to expand awareness and access to psychedelic-assisted therapy

INCUMBENTS_PRESENT

<div>
 <p>The Canadian company Numinus Wellness, which specializes in psychedelic substances, has formed a partnership with a body called the Multidisciplinary Association for Psychedelic Studies (MAPS). Their joint aim is to offer psychedelic experiences to practitioners as part of a clinical study.</p>
 <p>The arrangement is reliant on Health Canada approving Numinus's Clinical Trial Application (CTA). If this happens, Numinus will gain exclusivity over a clinical trial created for practitioners who wish to explore MDMA-assisted therapy. By observing and joining in MDMA sessions, practitioners hope to further their understanding of psychedelic-assisted therapy. </p>
 <p>The MDMA used in this clinical trial will be of clinical-grade and will be manufactured by Optimi. This company, also based in Canada, concentrates on producing and providing psychedelic substances to be utilized in clinical trials. To begin with, the trial will be based at Numinus's Vancouver clinics, but there is the possibility that it may be extended to other sites in the future. </p>
 
</div>

All Updates

Numinus partners with PharmAla Biotech for LaNeo MDMA supply in clinical trial

Numinus Wellness raises USD 6 million in bought deal funding for operational expenses

Numinus launches psychedelic program for mental distress associated with chronic and serious illness

Numinus Wellness provides financial and business update for Q3 FY2023

Numinus partners with HealingMaps to expand awareness and access to psychedelic-assisted therapy

Numinus partners with MAPS to offer psychedelic experiential opportunities for practitioners

Numinus’ Cedar Clinical Research site to be used in MindMed's Phase IIb study on MM-120

Numinus to commence clinical study of COMP360 psilocybin therapy for treatment-resistant depression

Numinus Wellness provides financial and business update for Q2 FY2023

Numinus launches new clinic licensing platform and partners with Healing Commercial Real Estate